Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10159-2-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10159-2-AP, RRID:AB_2266881
- Product name
- MYCN antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated MYCN antibody (Cat. #10159-2-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references An E2F5-TFDP1-BRG1 Complex Mediates Transcriptional Activation of MYCN in Hepatocytes.
Comparative proteomics reveals Cryptosporidium parvum manipulation of the host cell molecular expression and immune response.
A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma.
Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms' Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities.
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells.
Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[18F]FGln PET Imaging.
Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
Fan Z, Kong M, Miao X, Guo Y, Ren H, Wang J, Wang S, Tang N, Shang L, Zhu Z, Liu H, Zhu W, Shi X
Frontiers in cell and developmental biology 2021;9:742319
Frontiers in cell and developmental biology 2021;9:742319
Comparative proteomics reveals Cryptosporidium parvum manipulation of the host cell molecular expression and immune response.
Li T, Liu H, Jiang N, Wang Y, Wang Y, Zhang J, Shen Y, Cao J
PLoS neglected tropical diseases 2021 Nov;15(11):e0009949
PLoS neglected tropical diseases 2021 Nov;15(11):e0009949
A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma.
Gifford AJ, Murray J, Fletcher JI, Marshall GM, Norris MD, Haber M
Current protocols 2021 Nov;1(11):e310
Current protocols 2021 Nov;1(11):e310
Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms' Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities.
Szemes M, Melegh Z, Bellamy J, Park JH, Chen B, Greenhough A, Catchpoole D, Malik K
Cancers 2021 Feb 6;13(4)
Cancers 2021 Feb 6;13(4)
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, Groth J, Foo WC, Liang C, Hu H, Huang J
Molecular cancer 2019 Jan 18;18(1):11
Molecular cancer 2019 Jan 18;18(1):11
Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells.
Lee YJ, Chang WW, Chang CP, Liu TY, Chuang CY, Qian K, Zheng YG, Li C
Scientific reports 2019 Feb 11;9(1):1771
Scientific reports 2019 Feb 11;9(1):1771
Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[18F]FGln PET Imaging.
Li C, Huang S, Guo J, Wang C, Huang Z, Huang R, Liu L, Liang S, Wang H
Molecular imaging and biology 2019 Dec;21(6):1117-1126
Molecular imaging and biology 2019 Dec;21(6):1117-1126
Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.
DeVore SB, Young CH, Li G, Sundararajan A, Ramaraj T, Mudge J, Schilkey F, Muth A, Thompson PR, Cherrington BD
Molecular and cellular biology 2018 Oct 1;38(19)
Molecular and cellular biology 2018 Oct 1;38(19)
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.
Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F
eLife 2017 Apr 20;6
eLife 2017 Apr 20;6
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC
Frontiers in oncology 2015;5:111
Frontiers in oncology 2015;5:111
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H
Cancer 2013 Oct 15;119(20):3718-26
Cancer 2013 Oct 15;119(20):3718-26
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H
Pediatric blood & cancer 2013 Mar;60(3):363-70
Pediatric blood & cancer 2013 Mar;60(3):363-70
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The MYCN antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human MYCN. This antibody recognizes human, mouse, rat antigen. The MYCN antibody has been validated for the following applications: ELISA, WB analysis.
